News COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.
News Digital osteoarthritis, bulimia tools backed for NHS use Guidance in the UK has cleared the way for NHS use of digital health technologies for people with osteoarthritis and eating disorder bulimia.
News Change of heart as NICE backs prostate cancer drug Talzenna Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.
News NICE backs Roche lupus drug that supports kidney function Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.
News NICE relents, ending postcode access to prostate cancer drug Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.
News NICE endorses digital tools for people with asthma Eight digital health technologies (DHTs) designed to support people with asthma can be used by the NHS in England, according to NICE.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.